Importantly, a THBS1 threshold of 7 ng/ml serum could correctly categorize 17/18 (94%) tested samples as adenocarcinomas and 4/6 CRPC-NE (67%) samples as those with therapy-induced NED. Here, THBS1 is linked to adenocarcinoma.